Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma. [electronic resource]
Producer: 19981216Description: S18-21 p. digitalISSN:- 0959-8049
- Antineoplastic Agents -- economics
- Cohort Studies
- Combined Modality Therapy -- economics
- Cost-Benefit Analysis
- Disease-Free Survival
- Health Care Costs
- Humans
- Interferon alpha-2
- Interferon-alpha -- economics
- Melanoma -- therapy
- Middle Aged
- Recombinant Proteins
- Skin Neoplasms -- therapy
- Survival Rate
- Virginia
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.